From Montreal: Ocythera is developing a treatment for rare bone disorders that targets the retinoic acid pathway without using retinoids
Interim CEO Joseph Mancini describes how Ocythera's solution inhibits an enzyme and how this approach has shown to not have the toxicity issues in preclinical studies that retinoids have seen. Plus, how Montreal's adMare BioInnovations has been critical to Ocythera's early work.









.png)
